QA102 fase II-studie i forsøgspersoner med tør AMD (AMEND)
En fase 2, dobbeltmaskeret, randomiseret, placebokontrolleret, dosis-respons undersøgelse, der vurderer sikkerheden og effektiviteten af QA102 hos forsøgspersoner med tør aldersrelateret makuladegeneration (AMD)
This is a phase 2, double-masked, randomized, placebo-controlled, dose-response study. The primary objective of the study is to evaluate the efficacy of QA102 oral capsules on the development of soft drusen, visual acuity (VA), and geographic atrophy (GA) or choroidal neovascularization (CNV) or the progression of GA in subjects with intermediate to advanced dry AMD.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Approximately 30 sites will randomize a total of approximately 150 subjects to 1 of 3 treatment arms in a 1:1:1 ratio (50 subjects per arm). Each subject will receive either QA102 or matching placebo BID for up to 15 months.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85021
- Associated Retina Consultants
-
-
California
-
Mountain View, California, Forenede Stater, 94040
- Northern California Retina Vitreous Associates Medical Group
-
Pasadena, California, Forenede Stater, 91107
- California Eye Specialists Medical Group
-
Redlands, California, Forenede Stater, 91107
- California Eye Specialists Medical Group
-
-
Colorado
-
Colorado Springs, Colorado, Forenede Stater, 80909
- Retina Consultants of Southern Colorado, P.C.
-
-
Florida
-
Deerfield Beach, Florida, Forenede Stater, 33064
- Advanced Research
-
Fort Myers, Florida, Forenede Stater, 33912
- National Ophthalmic Research Institute
-
Miami, Florida, Forenede Stater, 33143
- MedEye Associates
-
Pensacola, Florida, Forenede Stater, 32503
- Retina Specialty Institute
-
Pinellas Park, Florida, Forenede Stater, 33782
- Eye Associates of Pinellas
-
Sarasota, Florida, Forenede Stater, 34239
- Sarasota Retina Institute
-
Winter Haven, Florida, Forenede Stater, 33880
- Vitreous and Retina Consultants
-
-
Georgia
-
Marietta, Georgia, Forenede Stater, 30060
- Marietta Eye Clinic
-
-
Illinois
-
Oak Forest, Illinois, Forenede Stater, 60452
- University Retina and Macula Associates
-
-
Louisiana
-
West Monroe, Louisiana, Forenede Stater, 71291
- Northeast Louisiana dba Haik Humble Eye Center
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21209
- The Retina Care Center
-
Hagerstown, Maryland, Forenede Stater, 21740
- Cumberland Valley Retina Consultants
-
Hagerstown, Maryland, Forenede Stater, 21740
- Mid Atlantic Retina Specialists
-
-
Massachusetts
-
Worcester, Massachusetts, Forenede Stater, 01605
- Vitreo-Retinal Associates, P.C.
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63144
- Retina Research Institute
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45202
- Velocity Clinical Research
-
-
Oregon
-
Eugene, Oregon, Forenede Stater, 97401
- Verum Research, LLC
-
-
Pennsylvania
-
Erie, Pennsylvania, Forenede Stater, 16507
- Erie Retina Research
-
-
Texas
-
Abilene, Texas, Forenede Stater, 79606
- Retina Research Institute of Texas
-
Austin, Texas, Forenede Stater, 78705
- Austin Research Center for Retina
-
Dallas, Texas, Forenede Stater, 75243
- AXIS Clinicals LLC / Retina of North Texas
-
Plano, Texas, Forenede Stater, 75075
- Texas Retina Associates - Plano
-
San Antonio, Texas, Forenede Stater, 78215
- San Antonio Eye Center
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84107
- Rocky Mountain Retina Consultants
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria:
- Subject must be able to understand and willing to sign a written informed consent form (ICF) prior to the initiation of any study-specific procedures.
- Subject must be age ≥50 years at the time of informed consent.
- Subject must be able to take oral medications and willing to record daily adherence to taking their assigned capsules.
- Subject must have adequate hematologic function, hepatic function, renal function and coagulation profile as defined in the protocol.
- Subject must be willing and able to comply with study procedures and examinations.
Specific to the Study Eye:
-
Subject must have one of the following:
- extensive intermediate-size drusen, or at least 1 large drusen, or
- GA ((not involving the foveal center point) secondary to AMD, with very limited aggregate size of total GA(s), as defined in the protocol.
-
Subject must be able to correctly identify ≥35 ETDRS letters (approximately 20/200 Snellen equivalent).
Specific to Fellow Eye:
- Subject must have a diagnosis of advanced AMD (evidence of GA and/or CNV), to be confirmed by the CRC.
Specific to Both Eyes:
- Subject must have visualizable retina, clear ocular media, and adequate pupillary dilation to ensure high-quality fundus imaging.
Key Exclusion Criteria:
- Subject received an active investigational drug within 6 weeks (or 5 half-lives of the active, whichever is longer) prior to screening for this QA102 study.
- Subject has ever received gene therapy (for any condition).
- Subject is unwilling to stop intake of Age-Related Eye Disease Studies (AREDS) vitamins for the duration of the study.
- Subject has a clinically significant systemic disease that might interfere with the study, in the judgment of the Investigator.
- Subject had major surgery within 30 days prior to Screening.
Specific to Study Eye:
- Subject has large GA, subfoveal GA, or active or inactive CNV, as confirmed by the CRC.
- Subject has GA or CNV due to causes other than AMD that that developed between Visit 1 (Screening) and Visit 2 (Randomization).
- Subject has endophthalmitis.
- Subject has a hemorrhagic or serous pigment epithelial detachment (PED) within 500 µm of the foveal center point, to be confirmed by the CRC.
- Subject has had retinal procedures or surgeries, or has a retinal pathology, such as a macular hole.
- Subject has aphakia or absence of the posterior capsule.
- Subject has ever received, whether in an interventional trial or by prescription, an FDA- approved treatment for GA. Use of such treatment during the QA102 study period also is prohibited. (Study Eye Only)
Specific to Fellow Eye:
Subject has monocular vision impairment, defined as having no light perception in the fellow eye with adequate vision in the study eye.
Specific to Either Eye:
- Subject had intraocular surgery with lens replacement within 3 months of Screening.
- Subject has any ophthalmic condition that could require surgery during the study period.
- Subject has an ocular condition that might affect adequate imaging of the retina and/or or alter visual acuity.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: QA102 200mg group
Subjects randomized to this arm will receive one (1) 200 mg capsule of QA102 and 1 placebo capsule BID = daily dose of 400 mg QA102 for up to 15 months |
Capsules |
|
Eksperimentel: QA102 400mg group
Subjects randomized to this arm will receive two (2) 200 mg capsules of QA102 BID = daily dose of 800 mg QA102 for up to 15 months |
Capsules |
|
Placebo komparator: Placebo group
Subjects randomized to this arm will receive two (2) placebo capsules BID = daily dose of 0 mg QA102 for up to 15 months |
Capsules |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change From Baseline in Soft Drusen Volume (mm3)
Tidsramme: Month 12
|
Change from baseline in soft drusen volume (mm3), Efficacy-Evaluable Analysis Set |
Month 12
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Mean Rate of GA Growth
Tidsramme: Month 12
|
Mean Rate of Growth in GA (mm2) (Square Root Transformation) from Baseline |
Month 12
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- QA102-CS201
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .